Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-26-058703
Filing Date
2026-05-11
Accepted
2026-05-11 16:43:16
Documents
71
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q chrs-20260331x10q.htm   iXBRL 10-Q 1982742
2 EX-31.1 chrs-20260331xex31d1.htm EX-31.1 13991
3 EX-31.2 chrs-20260331xex31d2.htm EX-31.2 14884
4 EX-32.1 chrs-20260331xex32d1.htm EX-32.1 12027
  Complete submission text file 0001104659-26-058703.txt   8241502

Data Files

Seq Description Document Type Size
5 EX-101.SCH chrs-20260331.xsd EX-101.SCH 58124
6 EX-101.CAL chrs-20260331_cal.xml EX-101.CAL 61495
7 EX-101.DEF chrs-20260331_def.xml EX-101.DEF 235003
8 EX-101.LAB chrs-20260331_lab.xml EX-101.LAB 473944
9 EX-101.PRE chrs-20260331_pre.xml EX-101.PRE 366240
77 EXTRACTED XBRL INSTANCE DOCUMENT chrs-20260331x10q_htm.xml XML 1402611
Mailing Address C/O DENNIS M. LANFEAR 333 TWIN DOLPHIN DR, SUITE 600 REDWOOD CITY CA 94065
Business Address C/O DENNIS M. LANFEAR 333 TWIN DOLPHIN DR, SUITE 600 REDWOOD CITY CA 94065 (650) 649-3530
Coherus Oncology, Inc. (Filer) CIK: 0001512762 (see all company filings)

EIN.: 273615821 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36721 | Film No.: 26963978
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)